Psychosis Polyrisk Score and Polygenic Risk Score to Improve Detection and Prognosis in Individuals at Clinical High Risk for Psychosis: Model Development and Internal Validation
Schizophrenia Bulletin · 2026
DOI: 10.1093/schbul/sbag088 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Dominic Oliver und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom. Hauptthemen laut MEDLINE: Psychotic Disorders, Schizophrenia, Gene-Environment Interaction, Disease Progression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The European Network of National Schizophrenia Networks Studying Gene- Environment Interactions, European Community's Seventh Framework Programme, UK Medical Research Council Fellowship.
Abstract (Originalsprache)
Background and Hypothesis Psychosis prevention can be supported by tools that facilitate the early detection of individuals at clinical high risk (CHR-P) and predicting their clinical outcomes. We aimed to use clinical, genetic, and environmental data to: (1) predict case–control status as a proof-of-concept for CHR-P detection, and (2) predict transition to psychosis. Study Design We used data from the European Network of National Schizophrenia Networks Studying Gene–Environment Interactions: a multicenter cohort study comprising 344 CHR-P individuals and 67 healthy controls. To predict CHR-P status, we used environmental (Psychosis Polyrisk Score [PPS]) and genetic (polygenic risk score for schizophrenia [PRS]) measures with logistic regression (LR) and random forest (RF). To predict transition to psychosis, we used clinical, environmental, and genetic measures with Cox proportional hazards model and random survival forest. Primary outcomes were discrimination (C-index) and calibration (intercept and slope) in repeated nested cross-validation. Clinical utility was assessed with decision curve analysis. Study Results For detection of CHR-P, both PPS (LR:C = 0.91, 95% CI, 0.87-0.94, intercept = 1.46, slope = 0.73; RF:C = 0.77, 95% CI, 0.61-0.90, intercept = −0.53, slope = 0.42) and PPS + PRS (LR:C = 0.89, 95% CI, 0.85-0.92, intercept = 1.45, slope = 0.73; RF:C = 0.78, 95% CI, 0.65-0.89, intercept = −0.24, slope = 0.44) had excellent discrimination performance, whereas PRS performed substantially worse (LR:C = 0.60, 95% CI, 0.52-0.67, intercept = 1.63, slope = 0.81; RF:C = 0.57, 95% CI, 0.41-0.72, intercept = −0.84, slope = 0.10). All models over-estimated risk in individuals with low observed risk. Prognosis model performance was poor (C ≤ 0.65). Conclusions CHR-P detection may be improved by using the PPS, though evidence is needed from more representative detection settings. However, we did not find evidence that baseline clinical, environmental and/or genetic data enhanced the prediction of psychosis onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom.
- NIHR Oxford Health Biomedical Research Centre, Oxford OX3 7JX, United Kingdom.
- OPEN Early Detection Service, Oxford Health NHS Foundation Trust, Oxford OX3 7JX, United Kingdom.
- Early Psychosis: Interventions and Clinical-Detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, United Kingdom.
- Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, United Kingdom.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia 27100, Italy.
ORCID-Profile: Dominic Oliver, Evangelos Vassos, Anita Riecher-Rössler, Neus Barrantes-Vidal, Gabriele Sachs, Daniel Stahl
Förderung
- The European Network of National Schizophrenia Networks Studying Gene- Environment Interactions
- European Community's Seventh Framework Programme
- UK Medical Research Council Fellowship
- MRC Doctoral Training Partnership in Biomedical Sciences
- National Institute for Health Research
- Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- NHMRC Investigator Grant
- NIHR Oxford Health Biomedical Research Centre
Zitieren
APA
Oliver, D., Arribas, M., Logeswaran, Y., Fusar-Poli, L., Kempton, M. J., Hedges, E. P., Albinaña, C., Vassos, E., Sariaslan, A., Pettersson-Yeo, W., Valmaggia, L., van der Gaag, M., de Haan, L., Nelson, B., McGorry, P., Riecher-Rössler, A., Studerus, E., Bressan, R., Barrantes-Vidal, N., …, & EU-GEI High Risk Study Group (2026). Psychosis Polyrisk Score and Polygenic Risk Score to Improve Detection and Prognosis in Individuals at Clinical High Risk for Psychosis: Model Development and Internal Validation. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbag088
Vancouver
Oliver D, Arribas M, Logeswaran Y, Fusar-Poli L, Kempton MJ, Hedges EP, et al. Psychosis Polyrisk Score and Polygenic Risk Score to Improve Detection and Prognosis in Individuals at Clinical High Risk for Psychosis: Model Development and Internal Validation. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbag088
BibTeX
@article{Oliver2026,
author = {Oliver, Dominic and Arribas, Maite and Logeswaran, Yanakan and Fusar-Poli, Laura and Kempton, Matthew J and Hedges, Emily P and Albinaña, Clara and Vassos, Evangelos and Sariaslan, Amir and Pettersson-Yeo, William and Valmaggia, Lucia and van der Gaag, Mark and de Haan, Lieuwe and Nelson, Barnaby and McGorry, Patrick and Riecher-Rössler, Anita and Studerus, Erich and Bressan, Rodrigo and Barrantes-Vidal, Neus and Krebs, Marie-Odile and Nordentoft, Merete and Ruhrmann, Stephan and Sachs, Gabriele and Rutten, Bart and van Os, Jim and Stahl, Daniel and McGuire, Philip and Fusar-Poli, Paolo and EU-GEI High Risk Study Group, EU-GEI High Risk Study Group},
title = {Psychosis Polyrisk Score and Polygenic Risk Score to Improve Detection and Prognosis in Individuals at Clinical High Risk for Psychosis: Model Development and Internal Validation},
journal = {Schizophrenia Bulletin},
year = {2026},
doi = {10.1093/schbul/sbag088}
}
EUVIMED